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Background: Normobaric hyperoxia is used to alleviate secondary
brain ischaemia in patients with traumatic brain injury (TBI), but
clinical evidence is limited and hyperoxia may cause adverse events.
Methods: An open label, randomised controlled pilot study com-
paring blood concentrations of reactive oxygen species (ROS),
interleukin 6 (IL-6) and neuron-specific enolase (NSE) between
two different fractions of inspired oxygen in severe TBI patients
on mechanical ventilation.
Results: We enrolled 27 patients in the Fi O2 0.40 group and 38
in the Fi O2 0.70 group; 19 and 23 patients, respectively, completed
biochemical analyses. In baseline, there were no differences
between Fi O2 0.40 and Fi O2 0.70 groups, respectively, in ROS
(64.8 nM [22.6–102.1] vs. 64.9 nM [26.8–96.3], P = 0.80), IL-6
(group 92.4 pg/ml [52.9–171.6] vs. 94.3 pg/ml [54.8–133.1],
P = 0.52) or NSE (21.04 ug/l [14.0–30.7] vs. 17.8 ug/l [14.1–23.9],
P = 0.35). ROS levels did not differ at Day 1 (24.2 nM [20.6–33.5]
vs. 29.2 nM [22.7–69.2], P = 0.10) or at Day 2 (25.4 nM [21.7–37.4]
vs. 47.3 nM [34.4–126.1], P = 0.95). IL-6 concentrations did not dif-
fer at Day 1 (112.7 pg/ml [65.9–168.9) vs. 83.9 pg/ml [51.8–144.3],
P = 0.41) or at Day 3 (55.0 pg/ml [34.2–115.6] vs. 49.3 pg/ml [34.4–
126.1], P = 0.95). NSE levels did not differ at Day 1 (15.9 ug/l [9.0–
24.3] vs. 15.3 ug/l [12.2–26.3], P = 0.62). There were no differences
between groups in the incidence of pulmonary complications.
Conclusion: Higher fraction of inspired oxygen did not increase
blood concentrations of markers of oxidative stress, inflammation
or neurological injury or the incidence of pulmonary complica-
tions in severe TBI patients on mechanical ventilation.
Editorial comment
While hypoxia must be avoided to limit or prevent secondary injury in patients with traumatic
brain injury, there is limited evidence to support benefit of hyperoxia. The results of the first 65
patients in a randomised, controlled trial of high (0.7) versus low (0.4) fractions of inspired oxygen
did not demonstrate any clear differences in oxidative stress, inflammation, or injury markers.
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ORIGINAL ARTICLE
Traumatic brain injury (TBI) is the leading
cause of death in young people,1 and disability
is a severe problem among survivors.2–4In TBI
patients, regional brain ischaemia is a common
finding, which may be related to low tissue oxy-
gen tension (PtiO2).
5,6The use of high fractions
of inspired oxygen is one intervention used to
correct low PtiO2. Moderate hyperoxia increases
the cerebral aerobic metabolism7 and has been
suggested as a means of improving outcomes
after TBI.7–9Experimental studies indicate that
normobaric hyperoxia improves the perilesional
tissue metabolic rate of oxygen.10,11 On the
other hand, normobaric hyperoxia is associated
with increased cerebral excitotoxity12 and
increased PaO2 has direct vasoconstrictive effect
on arterioles that in turn reduces cerebral blood
flow.13 One mechanism by which oxygen toxic-
ity occurs is the production and accumulation of
excessive reactive oxygen species (ROS),14–16
which can potentially exacerbate brain injury.17
Furthermore, TBI is associated with the activa-
tion of several inflammatory pathways, which
may be modulated by the amount of oxygen
available in tissue. The effects of hyperoxia on
inflammation are not well understood: normo-
baric hyperoxia increases inflammatory marker
release,18 whereas hyperbaric hyperoxia has
been shown to reduce levels of the proinflam-
matory marker interleukin 6 (IL-6)19, which is
associated with the neurological outcome.18
However, using a high fraction of inspired oxy-
gen has also been associated with pulmonary
adverse events, such as ventilation–perfusion
mismatch, pulmonary oedema and inflamma-
tion.20 A high concentration of inspired oxygen
may cause the formation of lung atelectasis, and
some studies even suggest an increase in mortal-
ity in general intensive care unit (ICU)
patients.19,21 There are no clinical studies on the
effect of the prolonged use of normobaric hyper-
oxia on inflammatory markers, markers of
oxidative stress and neurological injury in TBI.
Accordingly, in this pilot study, we compared
the effect of a ventilation strategy aiming at
moderate hyperoxaemia (FiO2 0.70) to a stan-
dard oxygen fraction (FiO2 0.40) in patients
with severe traumatic brain injury (Glasgow
Coma Score (GCS)< 8). We hypothesised that a
strategy using a higher oxygen fraction would
result in an alleviated inflammatory response
and lower markers of neurological injury, with-
out significantly increasing oxidative stress.
Materials and methods
Trial design, participants and setting
Trial design
BRAINOXY was a randomised, controlled, open
label pilot study comparing 0.70 and 0.40 oxy-
gen in mechanically ventilated intensive care
patients with severe traumatic brain injury. The
pilot study was performed in three Finnish
intensive care units (ICUs): Kuopio University
Hospital (KUH), Tampere University Hospital
(TAYS) and Helsinki University Central Hospi-
tal, T€o€ol€o Hospital (HUCH) during the period of
December 2010 to September 2013. The inclu-
sion criteria were as follows:
isolated non-penetrating TBI or multiple
trauma patient with TBI with Glasgow coma
scale (GCS) eight or less (inclusive), expected
need for intubation and mechanical ventilation
> 24 h, recruitment within 18 h after admission
to ICU and time from TBI < 36 h and informed
consent from next of kin.
Exclusion criteria were as follows: age < 18 or
> 65 years, anticipated brain death in 12 h or
otherwise moribund patient expected to die in
24 h, expected need for mechanical ventilation
< 24 h, insufficient oxygenation assessed by a
clinician or multiple trauma patients with brain
injury and severe abdominal, thoracic or pelvic
injury possibly affecting oxygenation, no con-
sent, insufficient oxygenation with the treatment
modality of the lower oxygenation group
(Pa02 < 13 kPa or SpO2 < 95% with Fi02 0.40
and PEEP of 10) or oxygenation failure probable
during ICU care, penetrating TBI, suspected
pregnancy (perform urinary or serological preg-
nancy test if suspected).
Randomisation procedure
We used sealed, opaque envelopes to randomly
divide patients into two intervention groups.
Patients were stratified according to TBI severity
(group GCS 3–5 and group GCS 6–8), whether
they had a surgically removed haematoma prior
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to ICU admission or diffuse brain injury, or
whether they had decompressive craniectomy
performed prior to randomisation. Patients had
to be included within 36 h from injury and 18 h
from admission to ICU. To exclude those
patients with a GCS< 8 due to a concomitant
intoxication and those who regained conscious-
ness immediately following operative treatment,
a sedation break was performed in the ICU and
this measured GCS was used as the inclusion
criterion.
Study intervention
Patients were randomly assigned to receive
either FiO2 0.40 or 0.70 of inspired oxygen dur-
ing the period of mechanical ventilation for a
maximum time of 14 days. Fi 0.40 and Fi 0.70
groups were chosen by a consensus decision in
the study management committee. Positive end
expiratory pressure (PEEP) of 8–10 was used to
minimise lung atelectasis. Otherwise, the
patient treatment was at the discretion of the
treating clinician, but it was recommended that
the Brain Trauma Foundation Guidelines be fol-
lowed (Appendix S1).
Laboratory sample handling and analysis
Laboratory samples were centrifuged and fro-
zen at 70°C. Serum was used for NSE analy-
ses and plasma for IL-6, ROS and RNS
analyses.
Neuron-specific enolase was analysed with
electrochemiluminescence immunoassay (ECLIA).
The reagent used in analysis was neuron-specific
enolase (NSE) (catalogue number 12133113 122,
Roche Diagnostics GmbH, Mannheim, Germany)
and the instrumentation used was the Cobas e 601
analyser (Hitachi High Technology Co., Tokyo,
Japan). The NSE was analysed only once. This
methodology is in clinical practise and our accred-
ited Kuopio University Hospital laboratory anal-
ysed all samples. The concentration of IL-6 in the
plasma was measured using a Sandwich enzyme-
linked immunosorbent assay (ELISA) kit
(BioLegend, San Diego, CA, USA) and the data
were calculated with computer-based, curve-
fitting software, after which the concentrations of
the samples were multiplied by the appropriate
dilution factor (1 : 1). IL-6 was measured in
duplicate.
Reactive oxygen species and RNS plasma
levels were measured using the OxiSelectTM In
Vitro ROS/RNS Assay Kit (Cell Biolabs, Inc.,
San Diego, CA, USA). All the patients were
sedated with propofol. Glycerol is an ingredient
in propofol solution. In this analysis, the con-
centration of glycerol in propofol was 2.5% and
in the compactible concentration range below
10%. The ROS assay was performed as per the
manufacturer’s instructions. ROS and RNS were
measured in duplicates.
Outcome variables and statistical considerations
Originally, when this study was designed, the
primary intention was to evaluate neurological
outcome at 6 months. Power analysis based on a
risk of poorer outcome than expected (death or
severe neurological injury) with 80% power at
5% significance level resulted at sample size of
500 patients (250 patients in both oxygen
groups) to detect a 10% decrease in poor out-
come. However, owing to a lack of funding and
a slow recruitment rate, the study is presented
as a pilot study with laboratory markers as the
surrogate outcome during the three-first days.
The analysis plan was approved in advance by
all authors. The agreed primary outcomes for
this were the levels of ROS, IL-6 and NSE over
time during ICU care. It was decided to focus
on patients remaining in the ICU for longer than
40 h. Post hoc power analysis (power 80% and
P = 0.05) based on mean values and standard
deviation of ROS/RNS values on Day 1 gave a
sample size of 123 patients.
Data collection
Data were collected with paper case record
forms (CRF), which included patient demo-
graphics, comorbidities, medications, pre-hospi-
tal treatment with relevant time points, clinical
status at arrival and type of trauma. Daily data
collection in the ICU included vital signs, neu-
rological status and acute physiology and
chronic health evaluation (APACHE II).22 Also
recorded were sequential organ failure assess-
ment (SOFA),23 chest X-rays, head computer
tomography (CT) classification according to the
Marshall classification,24 fluid balance, blood
transfusion and interventions aiming at decreas-
ing intracranial pressure, daily blood samples
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(arterial blood gases at least three times a day)
and respiratory management (ventilatory set-
tings, PaO2 : FiO2 ratio and static compliance).
Study-specific laboratory markers ROS/RNs, IL-
6 and NSE were measured at admission, Day 1
and/or Days 2 and 3. The Extended Glasgow
Outcome Scale (GOSE)25 was assessed by a
blinded neurologist at 6 months, after contact-
ing the patient or patient’s representative by
phone.
Statistical analysis
Categorical data are presented as absolute num-
bers, with percentages in parentheses. For com-
paring categorical data, we used a two-sided
chi-squared test or Fisher’s exact test when
appropriate. We tested all continuous data for
skewness, and these data are presented as medi-
ans with interquartile ranges (IQR), unless sta-
ted otherwise. We used the non-parametric
Mann–Whitney U-test for univariate compari-
son. Group levels of ROS, IL-6 and NSE over
time were compared by a linear mixed model,
using a variance component structure. The
change of ROS, IL-6 and NSE levels in the
groups over time was compared using the non-
parametric Friedman test (three time points) or
Wilcoxons signed-rank test (two time points).
We used statistical software SPSS version 22
(IBM SPSS Statistics, Armonk, NY, USA).
Ethical considerations
This pilot study was conducted according to the
principles of the Helsinki Declaration. The
ethics committee of Northern Savo, Finland
approved the study protocol number 93/2009.
Informed consent was obtained by the patient
representative prior to the study intervention. If
the patient regained capacity to give informed
consent, a deferred patient consent was
obtained.
Results
Of a total of 380 screened patients, 65 patients
were included, with 27 (42%) randomised to
the FiO2 0.40 group and 38 (58%) to the FiO2
0.70 group (Fig. 1). Altogether, 23 study
patients had incomplete laboratory tests at Day
2 or 3 and were subsequently excluded from the
analysis of laboratory markers, but their clinical
outcomes are presented. Patient baseline charac-
teristics are presented in Table 1. The mean
patient age was 43 + 17 years in the FiO2 0.4
group and 45 + 13 in the FiO2 0.70 group
(P = 0.97). Admission SOFA and APACHE II
scores were equal in both groups and no statis-
tical differences in the admission GCS were
observed (Table 1). The haemoglobin concentra-
tion was lower in the FiO2 0.70 group
(125 + 2 g/l) than in the FiO2 0.40 group
(131 + 2 g/l, P = 0.02). The risk of poor outcome
and death calculated with The International
mission for prognosis and analysis of clinical
trials in TBI prognostic calculator (TBI-
IMPACT)26 was higher in the FiO2 0.70 group
that FiO2 0.40 group, respectively (0.56 + 0.20
vs. 0.45 + 0.15, P < 0.03 and 0.35 + 0.16 vs.
0.25 + 0.15, P < 0.02). In the FiO2 0.70 group,
there were more patients with poor GCS and a
mass lesion in CT-scan Table 1).
Study intervention
In the FiO2 0.40 group, the mean FiO2 was 0.42
and in the FiO2 0.70 group it was 0.68
(P < 0.001). The median length of the study
intervention was 213 (116–318) h in the FiO2
0.40 group and 120 (64–159) h in the FiO2 0.70
group (P = 0.10). Patients in the FiO2 0.40
group had a longer length of ICU stay than
patients in the FiO2 0.70 group (273 [139–414]
h vs. 156 h [110–274], respectively) (P = 0.03).
Patients in the higher oxygen group had signifi-
cantly higher mean arterial blood oxygen ten-
sion than patients in the lower oxygen group
(P < 0.001). A higher oxygen fraction resulted,
as expected, in significantly higher mean oxygen
tension, without differences in mean carbon
dioxide (Table 2, Fig. 2). The oxygen tension in
arterial blood was 16.59 kPa in the FiO2 0.40
group and 29.09 kPa in the FiO2 0.70 group
(P < 0.001).
Differences in laboratory markers
Blood levels of ROS, IL-6 and NSE are shown
in Fig. 3. The number of patients in FiO2 0.40
group is 19 and the number of patients in FiO2
0.70 group is 23. The time delay from trauma to
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first blood sampling in FiO2 0.40 group was
12 h (7–23) and in FiO2 0.7 group 17 h (11–24),
P = 0.16. The first time point on the blood sam-
ples was taken in 24 h intervals. ROS concen-
trations were similar at admission, that is,
64.8 nM (22.6–102.1) in the FiO2 0.40 group
and 64.9 nM (26.8–96.3) in the FiO2 0.70 group
(P = 0.80). ROS concentrations were also similar
at Day 1, 24.2 nM (20.6–33.5) in the FiO2 0.40
group and 29.2 nM (22.7–69.2) in the higher
group (P = 0.10). At Day 2, ROS concentrations
were 25.4 nM (21.7–37.4) in the FiO2 0.40
group and 47.3 nM (34.4–126.1) in the FiO2
0.70 group (P = 0.95).
IL-6 concentrations were 92.4 pg/ml (52.9–
171.6) in the FiO2 0.40 group and 94.3 pg/ml
(54.8–133.1) in the higher inspired oxygen
group (P = 0.52). At Day 1, there were no signif-
icant differences in IL-6 concentrations between
the lower group (112.7 pg/ml [65.9–168.9]) and
the FiO2 0.70 group (83.9 pg/ml [51.8–144.3])
(P = 0.41). At Day 3, the IL-6 concentrations
were similar in the lower group (55.0 pg/ml
[34.2–115.6]) and the higher group (49.3 pg/ml
[34.4–126.1]) (P = 0.95).
NSE concentrations in both groups were simi-
lar at admission (FiO2 0.40 group 21.04 ug/l
[14.0–30.7] vs. FiO2 0.70 group 17.8 ug/l [14.1–
23.9]) (P = 0.35). At Day 1, the NSE concentra-
tion was 15.9 ug/l (9.0–24.3) in the FiO2 0.40
group and 15.3 ug/l (12.2–26.3) in the FiO2 0.70
group (P = 0.62).
Pulmonary complications and clinical
outcomes
The incidence of acute respiratory distress syn-
drome (ARDS), atelectasis formation and pneu-
monia were similar in both groups (ARDS
P = 0.067, atelectasis formation P = 0.722 and
pneumonia P = 0.534). The P /F-ratio was simi-
lar in both groups, P = 0.113 (Table 2, Fig-
ure S1).
Discussion
Key findings
In this pilot study conducted in mechanically
ventilated patients with severe TBI, the use of
an inspired oxygen fraction of 0.70 compared to
0.40 did not increase markers of oxidative stress,
inflammation or neurological injury, measured
by levels of ROS, IL-6 and NSE. Although the
study is underpowered, the results suggest that
the use of a higher oxygen fraction is safe and
does not result in more pulmonary complica-
tions or a prolonged need for mechanical venti-
lation. Future studies are warranted to clarify
the role of normobaric hyperoxia in TBI
patients.
Comparison to previous studies
Exposure to hyperoxia has been investigated in
both animal and human studies. In animal stud-
ies, the effects of hyperoxia are contradictory. In
animal brain injury and ischaemia resuscitation
models, Ahn and by Hazeltom showed that
hyperoxia results in an increased inflammatory
response and that normoxaemia reduces oxida-
tive damage to the brain, measured by levels of
ROS.17,27In these studies, the animals were
exposed to hyperoxia for 1 h only. The vast
majority of animal studies suggest that short
periods of hyperoxia do not promote additional
Fig. 1. Study flowchart.
Acta Anaesthesiologica Scandinavica 62 (2018) 801–810
ª 2018 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd 805
MODERATE HYPEROXEMIA IN TBI
free radical production,28 and the effects of
hyperoxia on oxidative stress seem to be time-
dependent. In the present pilot study, although
the exposure to hyperoxia lasted for
165 + 108 h, we failed to show any difference
in the oxidative stress between groups. Fujita
et al9 studied the effect of early-stage hyperox-
aemia on neurological outcome in patients with
Table 1 Baseline characteristics.
FiO2 0.40 n = 27 (42%) FiO2 0.70 n = 38 (58%) P
Patient characteristics
Age, years 43 + 17 45 + 13 0.971
Gender, M/F 23/4 31/7 0.751
Height, cm 178 (175–180) 180 (170–181) 0.558
Weight, kg 82 + 15 79 + 13 0.516
Comorbidities
Heart disease 6 7 0.706
Neurological disease 1 2 0.628
Pulmonary disease 1 5 0.197
Diabetes 6 9 0.991
Anticoagulation therapy 1 1 0.152
Severity of TBI
Pupils
Both reacting 19 25 0.839
One reacting 7 10
Both unreactive 1 2
Pre-hospital hypoxia, SpO2 < 90% 5 (19%) 10 (26%) 0.569
Pre-hospital hypotension,
SAP < 90 mmHg
5 (19%) 2 (5%) 0.612
Worst GCS within 24 h from admission
3 10 20 0.667
4 5 7
5 5 3
6 3 3
7 3 2
8 1 2
Marshall CT category
1 0 0 0.443
2 8 6
3 4 5
4 2 2
5 4 4
6 8 20
Hb concentration g/l on admission 131 + 19 125 + 22 0.020
Risk of poor outcome (TBI-IMPACT) 0.45 + 0.21 0.56 + 0.20 0.033
Risk of death (TBI-IMPACT) 0.25 + 0.15 0.35 + 0.16 0.016
Delay from trauma to neurosurgical ICU, h 2 (1–4) 4 (2–10) 0.824
General severity of illness
SOFA 10 + 2.7 10 + 2.8 0.277
APACHE II 22 + 5 23 + 5 0.342
Blood glucose on admission mg/l 7.8 + 2.9 8.2 + 3.1 0.985
Thrombocyte count on admission 9 103/ll 197 (148–227) 192 (133–241) 0.917
Continuous data are presented as mean (SD) or median (IQR). For normally distributed data, the v2-test (Bonferroni correction) was used
and, when the expected value was below 5, the Fischer’s exact test was used. For non-parametric continuous data, the Mann–Whitney U-test
was used. SD, standard deviation; IQR, interquartile range; SOFA, sequential organ failure assessment; APACHE II, Acute Physiology and
Chronic Health Evaluation; ICU, intensive care unit; SAP, systolic blood pressure; MAP, mean arterial pressure; eGOSE, extended Glasgow
Outcome Scale; TBI-IMPACT, International mission for prognosis and analysis of clinical trials in TBI prognostic calculator.
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TBI. They found hyperoxia to be beneficial in
terms of neurological outcome and survival
although the intervention lasted for only 24 h
and these patients were either fever controlled
or experiencing mild hypothermia.
Most studies on hyperoxia in patients with
TBI are retrospective and assess the impact of
hyperoxia on the crude outcome. Generally,
hyperoxia is associated with increased mortality,
but the interpretation of such results is chal-
lenging, owing to the heterogeneity of the stud-
ies.29
In humans, Puccio et al30 studied the effect of
hyperoxia on patients with severe TBI. They
ventilated the patients for 2 h with FiO2 1.0 and
found that hyperoxia did not increase oxidative
stress markers. This is in accordance with our
pilot study, which suggests that even prolonged
exposure to higher oxygen does not increase
oxidative stress, inflammation or neurological
injury.
The association of oxidative stress and inflam-
mation is complex. In in vitro models, hyper-
oxia has been shown to increase ROS, which in
turn results in the generation of intracellular
inflammatory markers such as IL-6 and IL-8 in
lung tissue.15 Theoretically, hyperoxia-induced
lung injury results from direct oxygen toxicity
and the accumulation of inflammatory mediators
in the lung tissue.15 Hyperoxia-induced lung
injury (HALI) is proportional to PaO2 and expo-
sure duration.31 However, the duration of
Table 2 Study outcomes.
FiO2 0.40, n = 27 (42%) FiO2 0.70, n = 38 (58%) P
Arterial blood gases
PaO2 kPa 16.59 + 5.66 29.09 + 12.34 < 0.001
PaCO2 kPa 4.71 + 0.91 4.65 + 0.81 0.9
Pulmonary function
P/F ratio 338 + 76 367 + 68 0.113
ARDS (n) 3 0 0.067
Atelectasis formation (n) 14 18 0.722
Pneumonia (n) 6 6 0.534
Outcome
Length of mechanical ventilation, h 151 (113–240) 121 (59–180) 0.441
Length of ICU stay, h 273 (139–414) 156 (110–274) 0.029
Length of hospital stay, h 374 (279–638) 277 (135–479) 0.116
Death (n) 8 9 1.00
eGOSE at 6 months (n)
Good (7–8) 3 8 0.583
Moderate (2–6) 15 19
Poor (1–2) 8 10
Continuous data are presented as mean (SD) or median (IQR). For normally distributed data, the v 2-test (Bonferroni correction) was used
and, when the expected value was below 5, the Fischer’s exact test was used. For non-parametric continuous data, the Mann–Whitney U-test
was used. SD, standard deviation; IQR, interquartile range; P/R ratio, ratio of arterial oxygen partial pressure to fractional inspired oxygen;
ICU, intensive care unit; ARDS, Acute respiratory distress syndrome; eGOSE, Extended Glasgow outcome scale.
Fig. 2. The mean and standard deviation of tension of oxygen and
carbon dioxide in the intervention groups.
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hyperoxia leading to pulmonary toxicity is
unknown.32 Conservative oxygen therapy is
associated with less radiological atelectasis for-
mation, but its clinical impact is unclear.33 In a
retrospective observational study, hyperoxia was
independently associated with ventilator-
induced pneumonia,34 but another study found
that hyperoxia did not affect ICU or hospital
length of stay.35 The present pilot study did not
exhibit any adverse effects of hyperoxia on
lungs; indeed, to the contrary, the FiO2 0.40
group had a longer ICU length of stay.
It must be kept in mind that neuroinflamma-
tion has both beneficial and detrimental effects
on the brain after TBI. It promotes the reparation
and regeneration processes of the primary injury;
on the other hand, it may worsen secondary brain
injury.36 In our pilot study, even NSE concentra-
tions were equal in both study groups, suggest-
ing that hyperoxia in this complex setting does
not negatively affect brain tissue.
We are not aware of any other randomised
studies with severe TBI in which hyperoxia has
been studied to a standard of FiO2 of 0.40. Gen-
erally, conservative oxygen therapy is associated
with a shorter duration of mechanical ventila-
tion33,37and more ventilator-free days, without
an impact on ICU mortality.37 The present pilot
study was unable to confirm these findings.
Limitations
First, the present pilot study was designed to be
a randomised controlled trial with a patient-
centred outcome as the endpoint. However,
owing to lack of funding and slow recruitment,
the study was terminated and is therefore study
is presented as a pilot study with laboratory
markers as primary outcome. Secondly, there
was a difference in severity of TBI according to
the TBI-IMPACT model between groups, and
this may have influenced the study findings.
Conclusion
In the current pilot study, prolonged use of an
inspired fraction of oxygen of 0.70 compared to
0.40 did not affect the blood levels of markers of
oxidative stress, inflammation or neurological
injury. In addition, we found no difference in
pulmonary complications between the groups.
Further studies are needed to evaluate the
impact of using higher oxygen fractions on neu-
rological outcome after severe TBI.
References
1. Tieves KS, Yang H, Layde PM. The epidemiology of
traumatic brain injury in Wisconsin, 2001. WMJ
2005; 104: 22–5.
2. Narayan RK, Michel ME, Ansell B, Baethmann A,
Biegon A, Bracken MB, Bullock MR, Choi SC,
Clifton GL, Contant CF, Coplin WM, Dietrich WD,
Ghajar J, Grady SM, Grossman RG, Hall ED,
Heetderks W, Hovda DA, Jallo J, Katz RL, Knoller
N, Kochanek PM, Maas AI, Majde J, Marion DW,
Marmarou A, Marshall LF, McIntosh TK, Miller E,
Mohberg N, Muizelaar JP, Pitts LH, Quinn P,
Riesenfeld G, Robertson CS, Strauss KI, Teasdale
G, Temkin N, Tuma R, Wade C, Walker MD,
Weinrich M, Whyte J, Wilberger J, Young AB,
Yurkewicz L. Clinical trials in head injury. J
Neurotrauma 2002; 19: 503–57.
Fig. 3. A, B, C Median and interquartile range blood levels of neuron-specific enolase (NSE), reactive oxygen species (ROS/RNS) and interleukin-6
(IL-6).
Acta Anaesthesiologica Scandinavica 62 (2018) 801–810
808 ª 2018 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
M. LANG ET AL.
3. Utomo WK, Gabbe BJ, Simpson PM, Cameron PA.
Predictors of in-hospital mortality and 6-month
functional outcomes in older adults after moderate to
severe traumatic brain injury. Injury 2009; 40: 973–7.
4. Zaloshnja E, Miller T, Langlois JA, Selassie AW.
Prevalence of long-term disability from traumatic
brain injury in the civilian population of the United
States, 2005. J Head Trauma Rehabil 2008; 23: 394–
400.
5. Chang JJ, Youn TS, Benson D, Mattick H, Andrade
N, Harper CR, Moore CB, Madden CJ, Diaz-Arrastia
RR. Physiologic and functional outcome correlates
of brain tissue hypoxia in traumatic brain injury.
Crit Care Med 2009; 37: 283–90.
6. Murray GD, Butcher I, McHugh GS, Lu J,
Mushkudiani NA, Maas AI, Marmarou A,
Steyerberg EW. Multivariable prognostic analysis in
traumatic brain injury: results from the IMPACT
study. J Neurotrauma 2007; 24: 329–37.
7. Tisdall MM, Tachtsidis I, Leung TS, Elwell CE,
Smith M. Increase in cerebral aerobic metabolism
by normobaric hyperoxia after traumatic brain
injury. J Neurosurg 2008; 109: 424–32.
8. Stover JF. Normobaric hyperoxia–a further
treatment option following traumatic brain injury?
Crit Care Med 2008; 36: 1697–8.
9. Fujita M, Oda Y, Yamashita S, Kaneda K, Kaneko
T, Suehiro E, Dohi K, Kuroda Y, Kobata H, Tsuruta
R, Maekawa T. Early-stage hyperoxia is associated
with favorable neurological outcomes and survival
after severe traumatic brain injury: a post-hoc
analysis of the brain hypothermia study. J
Neurotrauma 2017.
10. Nortje J, Coles JP, Timofeev I, Fryer TD, Aigbirhio
FI, Smielewski P, Outtrim JG, Chatfield DA,
Pickard JD, Hutchinson PJ, Gupta AK, Menon DK.
Effect of hyperoxia on regional oxygenation and
metabolism after severe traumatic brain injury:
preliminary findings. Crit Care Med 2008; 36: 273–
81.
11. Signoretti S, Marmarou A, Aygok GA, Fatouros PP,
Portella G, Bullock RM. Assessment of
mitochondrial impairment in traumatic brain injury
using high-resolution proton magnetic resonance
spectroscopy. J Neurosurg 2008; 108: 42–52.
12. Quintard H, Patet C, Suys T, Marques-Vidal P,
Oddo M. Normobaric hyperoxia is associated with
increased cerebral excitotoxicity after severe
traumatic brain injury. Neurocrit Care 2015; 22:
243–50.
13. Bulte DP, Chiarelli PA, Wise RG, Jezzard P.
Cerebral perfusion response to hyperoxia. J Cereb
Blood Flow Metab 2007; 27: 69–75.
14. Brenner M, Stein D, Hu P, Kufera J, Wooford M,
Scalea T. Association between early hyperoxia and
worse outcomes after traumatic brain injury. Arch
Surg 2012; 147: 1042–6.
15. Huang D, Fang F, Xu F. Hyperoxia induces
inflammation and regulates cytokine production in
alveolar epithelium through TLR2/4-NF-kappaB-
dependent mechanism. Eur Rev Med Pharmacol Sci
2016; 20: 1399–410.
16. Weaver J, Liu KJ. Does normobaric hyperoxia
increase oxidative stress in acute ischemic stroke?
A critical review of the literature. Med Gas Res
2015; 5: 11.
17. Ahn ES, Robertson CL, Vereczki V, Hoffman GE,
Fiskum G. Normoxic ventilatory resuscitation
following controlled cortical impact reduces
peroxynitrite-mediated protein nitration in the
hippocampus. J Neurosurg 2008; 108: 124–31.
18. Raheja A, Sinha S, Samson N, Bhoi S,
Subramanian A, Sharma P, Sharma BS. Serum
biomarkers as predictors of long-term outcome in
severe traumatic brain injury: analysis from a
randomized placebo-controlled Phase II clinical
trial. J Neurosurg 2016; 125: 631–41.
19. Fernandez-Perez ER, Sprung J, Afessa B, Warner
DO, Vachon CM, Schroeder DR, Brown DR,
Hubmayr RD, Gajic O. Intraoperative ventilator
settings and acute lung injury after elective surgery:
a nested case control study. Thorax 2009; 64: 121–7.
20. Martin DS, Grocott MP. Oxygen therapy in critical
illness: precise control of arterial oxygenation and
permissive hypoxemia. Crit Care Med 2013; 41:
423–32.
21. de Jonge E, Peelen L, Keijzers PJ, Joore H, de
Lange D, van der Voort PH, Bosman RJ, de Waal
RA, Wesselink R, de Keizer NF. Association
between administered oxygen, arterial partial
oxygen pressure and mortality in mechanically
ventilated intensive care unit patients. Crit Care
2008; 12: R156.
22. Knaus WA, Draper EA, Wagner DP, Zimmerman
JE. APACHE II: a severity of disease classification
system. Crit Care Med 1985; 13: 818–29.
23. Vincent JL, Moreno R, Takala J, Willatts S, De
Mendonca A, Bruining H, Reinhart CK, Suter PM,
Thijs LG. The SOFA (Sepsis-related Organ Failure
Assessment) score to describe organ dysfunction/
failure. On behalf of the Working Group on Sepsis-
Related Problems of the European Society of
Intensive Care Medicine. Intensive Care Med 1996;
22: 707–10.
24. Deepika A, Prabhuraj AR, Saikia A, Shukla D.
Comparison of predictability of Marshall and
Acta Anaesthesiologica Scandinavica 62 (2018) 801–810
ª 2018 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd 809
MODERATE HYPEROXEMIA IN TBI
Rotterdam CT scan scoring system in determining
early mortality after traumatic brain injury. Acta
Neurochir (Wien) 2015; 157: 2033–8.
25. Wilson JT, Pettigrew LE, Teasdale GM. Structured
interviews for the Glasgow Outcome Scale and the
extended Glasgow Outcome Scale: guidelines for
their use. J Neurotrauma 1998; 15: 573–85.
26. Marmarou A, Lu J, Butcher I, McHugh GS,
Mushkudiani NA, Murray GD, Steyerberg EW,
Maas AI. IMPACT database of traumatic brain
injury: design and description. J Neurotrauma
2007; 24: 239–50.
27. Hazelton JL, Balan I, Elmer GI, Kristian T,
Rosenthal RE, Krause G, Sanderson TH, Fiskum G.
Hyperoxic reperfusion after global cerebral ischemia
promotes inflammation and long-term hippocampal
neuronal death. J Neurotrauma 2010; 27: 753–62.
28. Doppenberg EM, Rice MR, Di X, Young HF,
Woodward JJ, Bullock R. Increased free radical
production due to subdural hematoma in the rat:
effect of increased inspired oxygen fraction. J
Neurotrauma 1998; 15: 337–47.
29. Damiani E, Adrario E, Girardis M, Romano R,
Pelaia P, Singer M, Donati A. Arterial hyperoxia
and mortality in critically ill patients: a systematic
review and meta-analysis. Crit Care 2014; 18:
711,014-0711-x.
30. Puccio AM, Hoffman LA, Bayir H, Zullo TG,
Fischer M, Darby J, Alexander S, Dixon CE,
Okonkwo DO, Kochanek PM. Effect of short
periods of normobaric hyperoxia on local brain
tissue oxygenation and cerebrospinal fluid
oxidative stress markers in severe traumatic brain
injury. J Neurotrauma 2009; 26: 1241–9.
31. Kallet RH, Matthay MA. Hyperoxic acute lung
injury. Respir Care 2013; 58: 123–41.
32. Hafner S, Beloncle F, Koch A, Radermacher P,
Asfar P. Hyperoxia in intensive care, emergency,
and peri-operative medicine: Dr Jekyll or Mr.
Hyde? A 2015 update. Ann Intensive Care
2015;5:42.
33. Suzuki S, Eastwood GM, Goodwin MD, Noe GD,
Smith PE, Glassford N, Schneider AG, Bellomo R.
Atelectasis and mechanical ventilation mode during
conservative oxygen therapy: a before-and-after
study. J Crit Care 2015; 30: 1232–7.
34. Six S, Jaffal K, Ledoux G, Jaillette E, Wallet F,
Nseir S. Hyperoxemia as a risk factor for ventilator-
associated pneumonia. Crit Care 2016; 20: 195,016-
1368-4.
35. Taher A, Pilehvari Z, Poorolajal J, Aghajanloo M.
Effects of normobaric hyperoxia in traumatic brain
injury: a randomized controlled clinical trial.
Trauma Mon 2016; 21: e26772.
36. Dong T, Zhi L, Bhayana B, Wu MX. Cortisol-
induced immune suppression by a blockade of
lymphocyte egress in traumatic brain injury. J
Neuroinflammation 2016; 13: 197.
37. Helmerhorst HJ, Roos-Blom MJ, van Westerloo DJ,
de Jonge E. Association between arterial hyperoxia
and outcome in subsets of critical illness: a
systematic review, meta-analysis, and meta-
regression of cohort studies. Crit Care Med 2015;
43: 1508–19.
Supporting Information
Additional Supporting Information may be
found in the online version of this article at the
publisher’s web-site:
Appendix S1. Head Injury Management Guide-
lines.
Figure S1. Mean and standard deviation of P/F-
ratio in the intervention groups.
Acta Anaesthesiologica Scandinavica 62 (2018) 801–810
810 ª 2018 The Acta Anaesthesiologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
M. LANG ET AL.
